Empirical data on the varicella situation in Germany for vaccinatin decisions

Clinical Microbiology and Infection

Volumn 10, Issue 5, 2004, Pages 425-430

  Wagenpfeil, Stefan ^a   Neiss, A ^a   Banz, K ^b   Wutzler, P ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Outcomes International   (Switzerland)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Chickenpox; Costs; Economic impact; Healthcare costs; Varicella

Indexed keywords

CHICKENPOX VACCINE;

ABSENTEEISM; ACUTE ABDOMEN; ADOLESCENT; ADULT; ARTICLE; BACTERIAL SUPERINFECTION; BRONCHITIS; CHICKENPOX; CHILD; CONJUNCTIVITIS; ECONOMIC EVALUATION; EMBRYOPATHY; EPIDEMIOLOGICAL DATA; FEMALE; GERMANY; HEALTH CARE COST; HEALTH INSURANCE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INFANT; KERATITIS; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MASS IMMUNIZATION; MEDICAL DECISION MAKING; MEDICAL PRACTICE; NEUROLOGIC DISEASE; NEWBORN; OTITIS MEDIA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZATION; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; THROMBOCYTOPENIA;

EID: 2642522324     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2004.00853.x     Document Type: Article

References (23)

1. Verschreibungsindex für Pharmazeutika (VIP). Requests: IMS HEALTH GmbH OHG, Hahnstr 2000. 30-2, 60528 Frankfurt am Main, [http://www.imshealth.de].
2. Ständige Impfkommission (STIKO) am Robert Koch-Institut. Impfempfehlungen/Stand. Juli 2001. Epidemiologisches Bull 2001; 28: 203-218.
3. Varis T, Vesikari T. Efficacy of high-titer live attenuated varicella vaccine in healthy young children. J Infect Dis 1996; 174 (suppl. 3): S330-S334.
4. Andre FE. Summary of clinical studies with the Oka live varicella vaccine produced by SmithKline RIT. Biken J 1984; 27: 89-98.
5. WHO. Weekly Epidemiol Record 1998; 32: 241-248.
6. Lieu TA, Cochi SL, Black SB et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994; 271: 375-381.
7. Coudeville L, Paree F, Lebrun T, Sailly J-C. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 1999; 17: 142-151.
8. Scuffham PA, Lowin AV, Burgess MA. The cost-effectiveness of varicella vaccine programs for Australia. Vaccine 2000; 18: 407-415.
9. Díez-Domingo J, Ridao M, Latour J, Ballester A, Morant A. A cost benefit analysis of routine varicella vaccination in Spain. Vaccine 1999; 17: 1306-1311.
10. Fornardo P, Gandini F, Marin M et al. Epidemiology and cost analysis of varicella in Italy: results of a sentinel study in the pediatric practice. Pediatr Infect Dis 1999; 18: 414-419.
11. Beutels P, Clara R, Tormans G, Van Doorslaer E, Van Damme P. Costs and benefits of routine varicella vaccination in German children. J Infect Dis 1996; 174 (suppl 3): 335-341.
12. Ferson MJ, Shen WL, Stark A. Direct and indirect costs of chickenpox in young children. J Paediatr Child Health 1998; 34: 18-21.
13. Wagenpfeil S, Neiss A, Goertz A, Bisanz H, Wutzler P. Varicella epidemiology in Germany for health economic analyses [abstract 58]. In: Program and abstracts of the 4th international conference on varicella zoster vaccination (VZV), La Jolla, CA, USA, 2001.
14. Wutzler P, Neiß A, Banz K, Tischer A. Ist eine Elimination der Varizellen durch eine allgemeine Impfung möglich?. Deutsches Ärzteblatt 2002; 99: 1024-1029.
15. Statistisches Bundesamt. Statistical Yearbook 2000 for the Federal Republic of Germany. Stuttgart: Metzler-Poeschel, 2000.
16. Wutzler P, Färber I, Wagenpfeil S, Bisanz H, Tischer A. Seroprevalence of varicella-zoster virus in the German population. Vaccine 2001; 20: 121-124.
17. Wutzler P, Banz K, Neiss A, Wagenpfeil S, Goertz A, Bisanz H. Seroepidemiological and health-economic data related to the strategy of varicella vaccination in Germany. Infection 2000; 78 (suppl 1): 18-19.
18. I+G Infratest und GfK Gesundheits- und Pharmamarkt Forschung. Varicella perception. Nürnberg, Germany, 1993.
19. EPIC. Encyclopaedia of Clinical Practice, Vol. 1.1 London: The G.P. Data Research Co. 1996.
20. Meyer PA, Seward JF, Jumaan AO, Wharon M. Varicella mortality: trends before vaccine licensure in the United States, 1970-94. J Infect Dis 2000; 182: 383-390.
21. Halloran ME, Watelet L, Struchiner C. Epidemiologic effects of vaccines with complex direct effects in an age-structured population. Math Biosci 1994; 121: 193-225.
22. Banz K, Staginnus U, Wagenpfeil S et al. Preliminary evaluation of the clinical and economic effects of universal varicella vaccination of children in Germany. Value Health 2000; 3: 297.
23. Banz K, Wagenpfeil S, Neiss A et al. The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine 2003; 21: 1256-1267.